FDA Approves Treatment for Multiple Rheumatologic Conditions

The FDA has approved Bimzelx for the treatment of adults with active psoriatic arthritis, active non-radiographic ...

SEPTEMBER 26, 2024

Upadacitinib Approved for Adults With Active Ankylosing Spondylitis

The FDA approved upadacitinib for the treatment of adults with active ankylosing spondylitis who have had an ...

MAY 4, 2022

FDA Approves Tofacitinib for Active Ankylosing Spondylitis

The FDA has approved a supplemental New Drug Application  for tofacitinib for the treatment of adults with ...

DECEMBER 17, 2021

Upadacitinib Receives FDA Approval for Active Psoriatic Arthritis

The FDA approved 15 mg of once-daily upadacitinib for the treatment of adults with active psoriatic arthritis who ...

DECEMBER 16, 2021

Multidisciplinary Specialty Care Team Approach Improves Biosimilar Adoption

A multidisciplinary specialty care team approach was significantly more successful in converting patients to ...

NOVEMBER 30, 2020

FDA Approves Biosimilar for Multiple Rheumatologic Conditions

The FDA approved adalimumab-bwwd, a biosimilar referencing adalimumab, for the treatment of rheumatoid arthritis, ...

AUGUST 28, 2019

Opioids Overused in Treatment of Ankylosing Spondylitis

Patients given opioids for ankylosing spondylitis may be getting a treatment that offers no real benefits and ...

MAY 3, 2018